Advertisement
Screener

MaxCyte, Inc. (MXCT) Graph

MXCT Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Cost of revenue $1.68M; Research and development $4.25M; Operating expenses $15.83M.
  • 2026-03-31: Revenue (m); Cost of revenue $1.57M; Research and development $3.86M; Operating expenses $14.27M.
  • 2025-12-31: Revenue (m); Cost of revenue $1.61M*; Research and development $3.33M*; Operating expenses $16.92M*.
  • 2025-09-30: Revenue (m); Cost of revenue $1.60M; Research and development $5.32M; Operating expenses $19.38M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30(m)$1.68M$4.25M$15.83M-$8.87M
2026-03-31(m)$1.57M$3.86M$14.27M-$4.75M
2025-12-31(m)$1.61M*$3.33M*$16.92M*-$9.60M*
2025-09-30(m)$1.60M$5.32M$19.38M-$12.42M
2025-06-30(m)$1.52M$6.27M$21.21M-$12.36M
2025-03-31(m)$1.50M$5.90M$21.19M-$10.26M
2024-09-30(m)$1.93M$5.32M$20.29M-$11.56M
2024-06-30(m)$1.49M$5.62M$20.91M-$9.38M
2024-03-31(m)$1.40M$6.68M$22.21M-$9.53M
2023-09-30(m)$793.00K$6.26M$21.16M-$11.25M
2023-06-30(m)$1.38M$5.66M$20.74M-$10.51M
2023-03-31(m)$1.00M$6.05M$20.75M-$10.88M
2022-09-30(m)$1.37M$5.33M$16.99M-$6.43M
2022-06-30(m)$1.12M$4.70M$17.23M-$8.26M
2022-03-31(m)$1.06M$3.77M$14.68M-$4.07M
2021-09-30(m)$943.80K$2.75M$11.64M-$2.68M
2021-06-30(m)$784.50K$3.20M$10.74M-$4.42M
2021-03-31(m)$693.10K$6.08M$12.17M-$7.11M
2020-09-30(m)$734.80K$4.52M$8.87M-$3.10M
2020-06-30(m)$466.30K$4.09M$7.53M-$3.00M
2020-03-31(m)(m)(m)(m)-$3.06M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30(m)$3.24M$8.11M$30.09M-$13.62M
2025-06-30(m)$3.02M$12.17M$42.40M-$22.62M
2024-06-30(m)$2.89M$12.30M$43.12M-$18.90M
2023-06-30(m)$2.38M$11.71M$41.49M-$21.39M
2022-06-30(m)$2.18M$8.46M$31.91M-$12.33M
2021-06-30(m)$1.48M$9.28M$22.92M-$11.53M
2020-06-30(m)$1.13M$8.34M$15.60M-$6.07M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2025-09-30(m)$4.61M$17.49M$61.78M-$35.03M
2024-09-30(m)$4.82M$17.61M$63.41M-$30.46M
2023-09-30(m)$3.17M$17.98M$62.66M-$32.65M
2022-09-30(m)$3.55M$13.79M$48.90M-$18.76M
2021-09-30(m)$2.42M$12.03M$34.55M-$14.21M
2020-09-30(m)$1.86M$12.85M$24.47M-$9.16M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$6.22M$20.82M$78.70M(m)-$44.63M
2024-12-31(m)$7.10M$22.23M$82.72M(m)-$41.05M
2023-12-31(m)$4.74M$23.82M$84.84M(m)-$37.92M
2022-12-31(m)$5.10M$19.51M$66.52M(m)-$23.57M
2021-12-31(m)$3.65M$15.41M$48.44M$0.00-$19.08M
2020-12-31(m)$2.77M$17.73M$34.46M$0.00-$11.82M
2019-12-31(m)$2.50M$17.59M$31.54M$0.00-$12.89M

Similar stocks

Stock NameCountryMarket CapPE Ratio
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14